Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandy Srinivas

Showing results (51-60 of 153) with videos related to

Pageof 16
Sort By:
Urologia Internationalis|July 11, 2006
Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapyI Jenna Liu, Yen-Han Lai, Jocelyn I Espiritu, et al.
Clinical Genitourinary Cancer|April 13, 2016
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial CancerSujata Narayanan, Anthony Lam, Ulka Vaishampayan, et al.
Cancer|May 20, 2008
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinomaEric Jonasch, Walter M Stadler, Ronald M Bukowski, et al.
Investigational New Drugs|April 7, 2010
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic diseaseRobert Dreicer, Jorge Garcia, Maha Hussain, et al.
BMC Urology|June 24, 2020
Physician preferences for non-metastatic castration-resistant prostate cancer treatmentSandy Srinivas, Ateesha F Mohamed, Sreevalsa Appukkuttan, et al.
Urology|July 19, 2011
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancerWilliam K Oh, Matthew D Galsky, Walter M Stadler, et al.
Urology|February 18, 2014
Utilization of renal mass biopsy in patients with renal cell carcinomaJohn T Leppert, Janet Hanley, Todd H Wagner, et al.
Urology|February 18, 2014
Reply: To PMID 24529583John T Leppert, Janet Hanley, Todd H Wagner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPCRoberto Pili, Mark A Rosenthal, Paul N Mainwaring, et al.
Future Oncology (London, England)|April 24, 2019
Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysisSeye Abogunrin, Ajibade O Ashaye, Joseph C Cappelleri, et al.
Pageof 16

Showing results (51-60 of 153) with videos related to

Sort By:
Pageof 16
Urologia Internationalis|July 11, 2006
Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapyI Jenna Liu, Yen-Han Lai, Jocelyn I Espiritu, et al.
Clinical Genitourinary Cancer|April 13, 2016
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial CancerSujata Narayanan, Anthony Lam, Ulka Vaishampayan, et al.
Cancer|May 20, 2008
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinomaEric Jonasch, Walter M Stadler, Ronald M Bukowski, et al.
Investigational New Drugs|April 7, 2010
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic diseaseRobert Dreicer, Jorge Garcia, Maha Hussain, et al.
BMC Urology|June 24, 2020
Physician preferences for non-metastatic castration-resistant prostate cancer treatmentSandy Srinivas, Ateesha F Mohamed, Sreevalsa Appukkuttan, et al.
Urology|July 19, 2011
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancerWilliam K Oh, Matthew D Galsky, Walter M Stadler, et al.
Urology|February 18, 2014
Utilization of renal mass biopsy in patients with renal cell carcinomaJohn T Leppert, Janet Hanley, Todd H Wagner, et al.
Urology|February 18, 2014
Reply: To PMID 24529583John T Leppert, Janet Hanley, Todd H Wagner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPCRoberto Pili, Mark A Rosenthal, Paul N Mainwaring, et al.
Future Oncology (London, England)|April 24, 2019
Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysisSeye Abogunrin, Ajibade O Ashaye, Joseph C Cappelleri, et al.
Pageof 16